3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
25
Neoplasms
5
Prostatic Neoplasms
4
Neoplasm Metastasis
3
Multiple Myeloma
2
Thyroid Neoplasms
1
Parathyroid Neoplasms
1
Osteoporotic Fractures
1
Osteoporosis
1
Osteopetrosis, mild autosomal recessive form
1
Osteopetrosis, Autosomal Recessive 7
1
Neoplastic Cells, Circulating
1
Musculoskeletal Pain
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Inflammatory Breast Neoplasms
1
Hypercalcemia
1
Humoral Hypercalcemia Of Malignancy
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Fractures, Bone
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Ductal, Breast
1
Breast Diseases
1
Bone Diseases, Metabolic
1
Arthralgia
1
Interventions
Cyclophosphamide
38
Paclitaxel
22
Epirubicin
21
Trastuzumab
20
Docetaxel
20
Doxorubicin
19
Carboplatin
15
Radiotherapy
13
Taxes
11
Filgrastim
11
Neoadjuvant Therapy
9
Bevacizumab
9
Fluorouracil
8
pembrolizumab
7
Tamoxifen
7
Albumin-Bound Paclitaxel
7
Capecitabine
6
pertuzumab
5
Thiotepa
5
Peripheral Blood Stem Cell Transplantation
5
Lapatinib
5
130-nm albumin-bound paclitaxel
5
pegfilgrastim
4
Granulocyte Colony-Stimulating Factor
4
Cisplatin
4
Chemotherapy, Adjuvant
4
Biopsy
4
tipifarnib
3
eribulin
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Inflammatory Breast Neoplasms
×
Denosumab
×
Breast
×
Clear all
NCT02682693
2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2
Completed
780 enrolled